The significant rise in the number of individuals that are affected by epidermolysis bullosa (EB) is one of the primary factors that is expected to drive the global dystrophic epidermolysis bullosa treatment market in the upcoming years. At present, dystrophic epidermolysis bullosa is the second most common type of epidermolysis bullosa and as per current observations, the number of cases is likely to grow at a consistent pace in the upcoming years. Thus, the demand for dystrophic epidermolysis bullosa treatment is on the rise.
Advancements in science and increasing focus on R&D activities are likely to provide an impetus to the overall development of the global dystrophic epidermolysis bullosa treatment market during the forecast period. The entry of whole-exome sequencing has revolutionized dystrophic epidermolysis bullosa diagnostics and treatment due to the development of gene panels across various epidermolysis bullosa treatment centers. This, in turn, has accelerated diagnosis and prognostication. In addition, due to the strides taken by gene editing, gene editing-based therapies are gaining immense popularity particularly for targeted treatment. At present, researchers involved in the current dystrophic epidermolysis bullosa treatment market are increasingly focusing on gaining a better understanding of the overall pathogenic mechanism of various subtypes of epidermolysis bullosa treatment, including dystrophic epidermolysis bullosa treatment.
At the back of these factors, the global dystrophic epidermolysis bullosa treatment market is on course to attain a market value of ~US$ 710 Mn by the end of 2030.
The increasing prevalence of epidermolysis bullosa– a set of hereditary skin blistering diseases has prompted researchers and scientists to seek newer treatment modalities – a factor that is expected to drive the global dystrophic epidermolysis bullosa treatment market during the assessment period. Furthermore, as researchers have gained immense knowledge pertaining to the genetic mutation of dystrophic epidermolysis bullosa, newer treatment modalities are currently making inroads into the global dystrophic epidermolysis bullosa treatment market. The increasing understanding of disease etio-pathogenesis is a top factor that is accelerating the development of new and cutting-edge therapy alternatives. In the current scenario, cell-based and first gene therapies are increasingly being tested in clinical trials and at the preclinical level. Moreover, the increasing knowledge of various secondary disease mechanisms has paved the way for clinical testing and development of symptom-relief therapies, including dystrophic epidermolysis bullosa treatment– a major factor that is anticipated to fuel the growth of the global dystrophic epidermolysis bullosa treatment market during the assessment period.
Due to the notable progress made by gene therapy and tissue engineering, dystrophic epidermolysis bullosa treatment has improved by a considerable margin. Moreover, apart from these alternatives, stem cell transplantation and gene correction are some of the other treatment alternatives that are likely to gain adoption in the global dystrophic epidermolysis bullosa treatment market during the assessment period. A number of research and development activities has indicated that in vitro gene therapy of keratinocyte stem cells and transplanting the same into the skin is one of the most promising and novel treatments that is likely to gain considerable adoption in the upcoming years. Scientists and stakeholders operating in the current dystrophic epidermolysis bullosa treatment market landscape are also focusing on enhancing the clinical features in epidermolysis bullosa patients by relying on in vitro gene therapy of stem cell keratinocytes– a factor that is projected to boost the global dystrophic epidermolysis bullosa treatment market during the assessment period.
The COVID-19 pandemic is expected to have a moderate impact on the overall growth of the global dystrophic epidermolysis bullosa treatment market during the assessment period. Research and development activities for dystrophic epidermolysis bullosa treatment are underway to identify the potential threat of the novel SARS-CoV-2 virus to patients suffering from dystrophic epidermolysis bullosa. Several studies have revealed that patients suffering from epidermolysis bullosa, particularly with syndromic forms are at a higher risk of acquiring the novel COVID-19 infection.
Overall, the outbreak of the COVID-19 pandemic is expected to accelerate research and development activities, thereby opening new avenues.
Analysts’ Viewpoint
The global dystrophic epidermolysis bullosa treatment market is expected to expand at a CAGR of ~5% during the forecast period. The market growth can be primarily attributed to increasing prevalence of epidermolysis bullosa worldwide, strides taken by gene editing, tissue engineering and stem cell technology, and rising investment for research and development. Market players are projected to focus on research and development and create awareness related to dystrophic epidermolysis bullosa treatment to gain a competitive edge.
Dystrophic epidermolysis bullosa treatment market to attain a market value of ~US$ 710 Mn by the end of 2030
Dystrophic epidermolysis bullosa treatment market is anticipated to expand at a CAGR of ~5% from 2020 to 2030
Dystrophic epidermolysis bullosa treatment market is driven by rise in prevalence of dystrophic epidermolysis bullosa and surge in research for managing dystrophic epidermolysis bullosa
North America dominated the global dystrophic epidermolysis bullosa treatment market in 2019 and the trend is anticipated to continue during the forecast period
Key players in the global dystrophic epidermolysis bullosa treatment market include Krystal Biotech, Castle Creek Biosciences, Inc., Abeona Therapeutics, Inc., Amryt Pharma plc, Wings Therapeutics, Phoenix Tissue Repair, InMed Pharmaceuticals, Inc., RegeneRx, and Holostem Terapie Avanzate S.r.l.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dystrophic Epidermolysis Bullosa Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Dystrophic Epidermolysis Bullosa Treatment Market Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, 2018–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Novel Therapies for Dystrophic Epidermolysis Bullosa Treatment
5.2. Pipeline Analysis
5.3. Potential Market of Phase 3 Pipeline Drug Therapies for Dystrophic Epidermolysis Bullosa
5.4. Epidemiology of Dystrophic Epidermolysis Bullosa
5.5. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)
5.6. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Type, 2018–2030
6.3.1. Antibiotics
6.3.2. Corticosteroids
6.3.3. Opioid Analgesics
6.3.4. Anticonvulsant
6.3.5. Others
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease Type, 2018–2030
7.3.1. Dominant Dystrophic Epidermolysis Bullosa
7.3.2. Recessive Dystrophic Epidermolysis Bullosa
7.4. Market Attractiveness Analysis, by Disease Type
8. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2018–2030
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2018–2030
10.2.1. Antibiotics
10.2.2. Corticosteroids
10.2.3. Opioid Analgesics
10.2.4. Anticonvulsant
10.2.5. Others
10.3. Market Value Forecast, by Disease Type, 2018–2030
10.3.1. Dominant Dystrophic Epidermolysis Bullosa
10.3.2. Recessive Dystrophic Epidermolysis Bullosa
10.4. Market Value Forecast, by Distribution Channel, 2018–2030
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Market Value Forecast, by Country, 2018–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By Disease Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Treatment Type, 2018–2030
11.2.1. Antibiotics
11.2.2. Corticosteroids
11.2.3. Opioid Analgesics
11.2.4. Anticonvulsant
11.2.5. Others
11.3.Market Value Forecast, by Disease Type, 2018–2030
11.3.1. Dominant Dystrophic Epidermolysis Bullosa
11.3.2. Recessive Dystrophic Epidermolysis Bullosa
11.4.Market Value Forecast, by Distribution Channel, 2018–2030
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5.Market Value Forecast, by Country/Sub-region, 2018–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6.Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By Disease Type
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast, by Treatment Type, 2018–2030
12.2.1. Antibiotics
12.2.2. Corticosteroids
12.2.3. Opioid Analgesics
12.2.4. Anticonvulsant
12.2.5. Others
12.3.Market Value Forecast, by Disease Type, 2018–2030
12.3.1. Dominant Dystrophic Epidermolysis Bullosa
12.3.2. Recessive Dystrophic Epidermolysis Bullosa
12.4.Market Value Forecast, by Distribution Channel, 2018–2030
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5.Market Value Forecast, by Country/Sub-region, 2018–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6.Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By Disease Type
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast, by Treatment Type, 2018–2030
13.2.1. Antibiotics
13.2.2. Corticosteroids
13.2.3. Opioid Analgesics
13.2.4. Anticonvulsant
13.2.5. Others
13.3.Market Value Forecast, by Disease Type, 2018–2030
13.3.1. Dominant Dystrophic Epidermolysis Bullosa
13.3.2. Recessive Dystrophic Epidermolysis Bullosa
13.4.Market Value Forecast, by Distribution Channel, 2018–2030
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others
13.5.Market Value Forecast, by Country/Sub-region, 2018–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6.Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By Disease Type
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast
14.1.Introduction
14.1.1. Key Findings
14.2.Market Value Forecast, by Treatment Type, 2018–2030
14.2.1. Antibiotics
14.2.2. Corticosteroids
14.2.3. Opioid Analgesics
14.2.4. Anticonvulsant
14.2.5. Others
14.3.Market Value Forecast, by Disease Type, 2018–2030
14.3.1. Dominant Dystrophic Epidermolysis Bullosa
14.3.2. Recessive Dystrophic Epidermolysis Bullosa
14.4.Market Value Forecast, by Distribution Channel, 2018–2030
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Others
14.5.Market Value Forecast, by Country/Sub-region, 2018–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6.Market Attractiveness Analysis
14.6.1. By Treatment Type
14.6.2. By Disease Type
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competitive Landscape
15.1. Company Profiles
15.1.1. Krystal Biotech
15.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.1.2. Growth Strategies
15.1.1.3. SWOT Analysis
15.1.2. Castle Creek Biosciences, Inc.
15.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.2.2. Growth Strategies
15.1.2.3. SWOT Analysis
15.1.3. Abeona Therapeutics, Inc.
15.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.3.2. Growth Strategies
15.1.3.3. SWOT Analysis
15.1.4. Amryt Pharma plc
15.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.4.2. Growth Strategies
15.1.4.3. SWOT Analysis
15.1.5. Wings Therapeutics
15.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.5.2. Growth Strategies
15.1.5.3. SWOT Analysis
15.1.6. Phoenix Tissue Repair
15.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.6.2. Growth Strategies
15.1.6.3. SWOT Analysis
15.1.7. InMed Pharmaceuticals, Inc.
15.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.7.2. Growth Strategies
15.1.7.3. SWOT Analysis
15.1.8. RegeneRx
15.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.8.2. Growth Strategies
15.1.8.3. SWOT Analysis
15.1.9. Holostem Terapie Avanzate S.r.l.
15.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.9.2. Growth Strategies
15.1.9.3. SWOT Analysis
List of Tables
Table 01: Global Dystrophic Epidermolysis Bullosa Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2030
Table 02: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 03: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 04: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 05: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 06: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 07: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 08: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 09: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 10: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 11: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 12: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel ,2018–2030
Table 13: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 15: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 16: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 17: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 18: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 19: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 20: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel ,2018–2030
Table 21: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 22: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 23: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 24: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
List of Figure
Figure 01: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Disease Type, 2019
Figure 03: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Region, 2019
Figure 04: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Treatment Type, 2019
Figure 05: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Distribution Channel, 2019
Figure 06: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030
Figure 07: Global Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Treatment Type, 2020–2030
Figure 08: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Antibiotics, 2018–2030
Figure 09: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Transport Medium, 2018–2030
Figure 10: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Opioid Analgesics, 2018–2030
Figure 11: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Anticonvulsant, 2018–2030
Figure 12: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Others, 2018–2030
Figure 13: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 14: Global Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030
Figure 15: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Dominant Dystrophic Epidermolysis Bullosa (DDEB), 2018–2030
Figure 16: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Recessive Dystrophic Epidermolysis Bullosa (RDEB), 2018–2030
Figure 17: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 18: Global Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 19: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2018–2030
Figure 20: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2018–2030
Figure 21: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Others, 2018–2030
Figure 22: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Region, 2019 and 2030
Figure 23: Global Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Region, 2020–2030
Figure 24: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 25: North America Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019–2030
Figure 26: North America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2030
Figure 27: North America Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030
Figure 28: North America Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019–2030
Figure 29: North America Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030
Figure 30: North America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030
Figure 31: North America Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 32: North America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 33: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 34: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019–2030
Figure 35: Europe Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2030
Figure 36: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030
Figure 37: Europe Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019–2030
Figure 38: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030
Figure 39: Europe Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030
Figure 40: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 41: Europe Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 42: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 43: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019–2030
Figure 44: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2030
Figure 45: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030
Figure 46: Asia Pacific Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019–2030
Figure 47: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030
Figure 48: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030
Figure 49: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 50: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 51: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 52: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019–2030
Figure 53: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2030
Figure 54: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030
Figure 55: Latin America Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019–2030
Figure 56: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030
Figure 57: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030
Figure 58: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 59: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 60: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 61: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019–2030
Figure 62: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2030
Figure 63: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030
Figure 64: Middle East & Africa Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019–2030
Figure 65: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030
Figure 66: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030
Figure 67: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 68: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Dystrophic Epidermolysis Bullosa Treatment Market
